478 reports of this reaction
1.5% of all LAPATINIB reports
#16 most reported adverse reaction
METASTASES TO CENTRAL NERVOUS SYSTEM is the #16 most commonly reported adverse reaction for LAPATINIB, manufactured by Novartis Pharmaceuticals Corporation. There are 478 FDA adverse event reports linking LAPATINIB to METASTASES TO CENTRAL NERVOUS SYSTEM. This represents approximately 1.5% of all 32,865 adverse event reports for this drug.
Patients taking LAPATINIB who experience metastases to central nervous system should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
METASTASES TO CENTRAL NERVOUS SYSTEM is a less commonly reported adverse event for LAPATINIB, but still significant enough to appear in the safety profile.
In addition to metastases to central nervous system, the following adverse reactions have been reported for LAPATINIB:
The following drugs have also been linked to metastases to central nervous system in FDA adverse event reports:
METASTASES TO CENTRAL NERVOUS SYSTEM has been reported as an adverse event in 478 FDA reports for LAPATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
METASTASES TO CENTRAL NERVOUS SYSTEM accounts for approximately 1.5% of all adverse event reports for LAPATINIB, making it a notable side effect.
If you experience metastases to central nervous system while taking LAPATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.